Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
This table compares Brainstorm Cell Therapeutics and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-236.80%||-115.34%|
Institutional and Insider Ownership
11.1% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Titan Pharmaceuticals shares are held by institutional investors. 22.6% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 6.5% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Brainstorm Cell Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Earnings & Valuation
This table compares Brainstorm Cell Therapeutics and Titan Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||N/A||-$13.95 million||N/A||N/A|
|Titan Pharmaceuticals||$6.62 million||2.31||-$9.02 million||($0.79)||-1.43|
Titan Pharmaceuticals has higher revenue and earnings than Brainstorm Cell Therapeutics.
This is a breakdown of recent ratings and recommmendations for Brainstorm Cell Therapeutics and Titan Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||3||0||3.00|
Brainstorm Cell Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 145.10%. Titan Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 253.98%. Given Titan Pharmaceuticals’ higher probable upside, analysts clearly believe Titan Pharmaceuticals is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics beats Titan Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.